We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medarex, Inc. and GenPat77 Pharmacogenetics AG, a privately held biopharmaceutical company focused on the development of immune modulatory products, have entered into a collaborative agreement to develop fully human therapeutic antibody products.
Barrier Therapeutics, Inc., a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the commercial launch of Denavir (penciclovir cream) 1% in Canada.
U.S. health officials should halt sales of estrogen and testosterone combinations made by Solvay SA and Breckenridge Pharmaceutical to treat hot flashes, a women's health group said.
CoGenesys, Inc. and Vegenics Limited announced that they have entered into a worldwide licensing agreement that provides Vegenics with rights to intellectual property in the field of vascular endothelial growth factors (VEGF).
Pharmaceutical industry groups have had a "less than enthusiastic response" to a bill (S 3818) sponsored by Sens. Orrin Hatch (R-Utah) and Patrick Leahy (D-Vt.) that would revise the U.S. patent system, CongressDaily reports.
Merck on Wednesday said the experimental arthritis drug Arcoxia, in a study, met its main goal of causing no more blood clot-related heart attacks than a standard treatment, but more patients taking Arcoxia withdrew from the trial due to serious side effects.
CDER has announced that its Advisory Committee for Pharmaceutical Science will hold a public meeting Oct. 5 and 6 in the agency's building at 5630 Fishers Lane, Rockville, Md.
The FDA has issued a warning letter to the Vail Valley Medical Center Institutional Review Board (IRB), saying that it was a conflict of interest for its vice chairman to vote to approve the protocol of a clinical trial that he himself had authored.
The controversial approval process for OTC sales of Barr Pharmaceuticals' Plan B contraceptive may be coming to an end, as the nation's commander-in-chief has indicated new conditions added to the application meet his approval.